# Quanterix receives $18.2M NIH contract for COVID-19 antigen test

Quanterix has entered into a Phase 2 contract with the National Institutes of Health worth $18.2 million to develop, scale up and deploy a SARS-CoV-2 antigen test based on its Simoa technology. The contract runs through September 2021.

- Type: Contract
- Announced: 2020-10-06
- Where: Billerica, Massachusetts, United States
- Value: $18.2M
- Status: announced
- Products: SARS-CoV-2 antigen test
- Sectors: [Medical Devices](https://endata.com/sectors/medical-devices.md)

## Companies

- [Quanterix](https://endata.com/companies/50384.md)
- [National Institutes of Health](https://endata.com/companies/48424.md) (customer)

## Sources

- [businesswire.com](https://www.businesswire.com/news/home/20201006006039/en/Quanterix-Receives-National-Institutes-of-Health-RADx-Contract-to-Advance-Antigen-Test-for-SARS-CoV-2-COVID-19), 2020-10-06: "The need for accurate and reliable testing in response to the global COVID-19 pandemic continues, and we are honored to have been selected by the NIH to progress to Phase 2 of this important initiative."

---
Data from Endata (https://endata.com/). Announcements are summarized from public sources and may be incomplete; check the linked originals.